ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1600

Anti-Ribosomal P Protein Antibodies Exacerbate Long-Term Prognosis In Patients With Diffuse Neuropsychiatric/Neuropsychological Syndromes In Systemic Lupus Erythematous

Yoshiyuki Arinuma1, Hirotoshi Kikuchi2, Eisuke Ogawa1, Tatsuhiko Wada1, Tatsuo Nagai3, Sumiaki Tanaka1 and Shunsei Hirohata1, 1Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, 2Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 3Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: autoantibodies, neuropsychiatric disorders and prognostic factors, SLE

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects II: Central Nervous System Manifestations, Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Systemic lupus erythematous (SLE) is a chronic inflammatory disease characterized by the expression of a variety of autoantibodies. Although the comprehensive survival from the disease has been improved in recent decades, neuropsychiatric manifestations in SLE (NPSLE) still remain one of the difficult complication. However, the factors that influence the long-term mortality in patients with NPSLE, especially diffuse neuropsychiatric/neuropsychological syndromes (diffuse NPSLE), have not been fully elucidated. Anti-ribosomal P protein antibodies (anti-P) are detected in 12–16% of patients with SLE, and have been shown to be associated with diffuse NPSLE. The aim of this study is to clarify the effects of various autoantibodies, including anti-P, on the overall mortality in patients with diffuse NPSLE.

Methods:  Fifty-eight patients with diffuse NPSLE (9 males and 49 females, ages 38.6 ± 17.0 years [mean ± SD]) who had been admitted to Kitasato University Hospital and to Teikyo University Hospital from 1992 to 2012 were exhaustively collected for the study. The medical charts were reviewed for various clinical parameters. The relationship of various serum autoantibodies with overall mortality was analyzed.

Results:  Of 58 patients, 12 patients [20.7%] died during the observation periods (2322 ± 2250 days [mean ± SD]) including 6 patients from SLE itself, 5 patients from infections and 1 patient from aortic aneurysm. The 5-year, 10-year and 15-year mortality rates based on the Kaplan-Meier method were 17.9%, 22.0% and 30.7%, respectively. The overall mortality was neither correlated with age nor with the duration of SLE at the onset of diffuse NPSLE. Among various autoantibodies in the sera, the presence of anti-P, but not that of anti-DNA, anti-Sm or anti-cardiolipin (CL) antibodies, at the onset of diffuse NPSLE, significantly increased the hazard ratio for death of the patients (p=0.0447). Moreover, on the Kaplan-Meier analysis, the survival rate was lower in patients with positive anti-P than those with negative anti-P at the onset (p=0.0711).

Conclusion:  These results indicate that the presence of anti-P in the sera is a significant risk factor for the poor prognosis of diffuse NPSLE.


Disclosure:

Y. Arinuma,
None;

H. Kikuchi,
None;

E. Ogawa,
None;

T. Wada,
None;

T. Nagai,
None;

S. Tanaka,
None;

S. Hirohata,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-ribosomal-p-protein-antibodies-exacerbate-long-term-prognosis-in-patients-with-diffuse-neuropsychiatricneuropsychological-syndromes-in-systemic-lupus-erythematous/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology